Paraneoplastic Cushing syndrome represents 5-10%
of all Cushing syndrome and has a severe prognosis
due to severe metabolic imbalance, denutrition,
associated infections and progression of tumoral
underlying pathology. The death is a rule in more
than 50% of cases. Some medication used to treat it –
Metirapone – is not available in Romania.
Ketoconazole was recently approved by CHMP for
treatment of paraneoplastic Cushing’s only in
November 2014.
